Results 121 to 130 of about 118,635,816 (237)
, 2017 Key Points The fVIII C1 domain contributes significantly to the immune response against fVIII in acquired and congenital hemophilia inhibitor patients. B-cell epitopes identified for monoclonal murine and human C1 inhibitors are recognized
Ernest T. Parker +10 more
core +1 more source
An In Vitro Study Simulating Prophylactic Anticoagulation in Haemophilia A and B
eJHaem, Volume 7, Issue 6, December 2026.ABSTRACT Introduction Patients with haemophilia A (HA) and haemophilia B (HB) are at increased bleeding risk. A recent guidance document suggests considering pharmacological thromboprophylaxis on a case‐by‐case basis in these patients undergoing surgery at high‐risk of venous thromboembolism.
Nicoletta Riva +8 more
wiley +1 more source
Determinants of Immune Tolerance Induction Outcomes in 237 Persons With Severe Hemophilia A
European Journal of Haematology, Volume 117, Issue 5, Page 1292-1300, November 2026.ABSTRACT Immune tolerance induction (ITI) to eradicate an immune response against factor VIII (FVIII) has been used in hemophilia A (HA) with various success rates, costs, and treatment burden. The present study aimed to identify markers predictive of ITI success.
Marcus Fager Ferrari +5 more
wiley +1 more source
Journal of Clinical Nursing, Volume 35, Issue 11, Page 4582-4628, November 2026.ABSTRACT Aim To identify and map evidence on factors that influence nurses' engagement in clinical research. Design A scoping review was conducted in accordance with the JBI methodology. Methods First, titles and abstracts of articles, then full‐text articles, were screened by two independent researchers against inclusion and exclusion criteria.
Lyndsay Jerusha Mackay +9 more
wiley +1 more source
Perfusion Cell Cultures: Is the Technology Worthwhile for Biopharmaceutical Production?
ChemBioEng Reviews, Volume 13, Issue 5, October 2026.The biotechnology industry is pursuing innovation and robust production, yet many biopharmaceuticals are manufactured from batch or fed‐batch cell cultures. Perfusion processes, offering higher yields and efficiency, remain underused despite their maturity.
Francesco Iannacci, Mattia Sponchioni
wiley +1 more source
FVIII hydrolysis mediated by anti-FVIII autoantibodies in acquired hemophilia
, 2008 International audienceAcquired hemophilia is a rare hemorrhagic disorder caused by the spontaneous appearance of inhibitory autoantibodies directed against endogenous coagulation factor VIII (FVIII).
Bayry, Jagadeesh +10 more
core +1 more source
Clinical Case Reports, Volume 14, Issue 10, October 2026.ABSTRACT Managing thrombosis in patients with bleeding disorders requires careful assessment of thromboembolic and bleeding risks, tailoring antithrombotic treatment in terms of type, dose, and duration, and considering the need for replacement therapy based on individual factor levels and bleeding history.
Synnøve Gjelsten Mortensen +4 more
wiley +1 more source
Epidermolysis bullosa acquisita (EBA) and acquired hemophilia A (AHA) are two rare autoimmune disorders. Respectively, EBA is an autoimmune blistering disease (AIBD) of the skin and mucous membranes, elicited by IgG autoantibodies against the collagen ...
Hertl, Michael +4 more
core +1 more source
Clinical Case Reports, Volume 14, Issue 10, October 2026.ABSTRACT A 7.6‐year‐old boy with hTTP had fever‐induced hemorrhagic rash, MAHA, cerebral infarction, and renal impairment. After plasma therapy, symptoms were partially relieved; 9‐year follow‐up showed regular plasma transfusion was needed, with CKD Stage 3.
Dai Xiaomei +5 more
wiley +1 more source
CD4+ T Cell Response to Factor VIII in Hemophilia A, Acquired Hemophilia, and Healthy Subjects
, 1999 IntroductionIn spite of the significant advances in the treatment of hemophilia over the last 30 years, the development of antibodies that neutralize the procoagulant activity of factor VIII (factor VIII inhibitors) remains a serious complication of ...
H. Wu +6 more
core +1 more source